Country Progress Report
Reporting Period
January – December, 2014
Accessed: 26.09.2019
The recommendations in these guidelines promote the use of simple, non-invasive diagnostic tests to assess the stage of liver disease and eligibility for treatment; prioritize treatment for those with most advanced liver disease and at greatest risk of mortality; and recommend the preferred use of n...ucleos(t)ide analogues with a high barrier to drug resistance (tenofovir and entecavir, and entecavir in children aged 2–11 years) for first- and second-line treatment. Recommendations for the treatment of HBV/HIV-coinfected persons are based on the WHO 2013 Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, which will be updated in 2015.
more
Article from the CDC Health Alert Network
Coordinated Use of Anthelminthic Drugs in Control Interventions: a Manual for Health Professionals and Programme Managers
- Twenty-two joint integrated rapid response mechanism (IRRM) missions were conducted in 11 counties and reached 305,887 people including 65,432 children under 5 years of age.
- UNICEF’s Integrated Community Mobilization Network reached 345,219 households (total population 2.1 million) advoca...ting for child rights focused on child survival, birth notification, education and protection. Three million people have been reached with advocacy and life-saving messages through radio and community engagement activities, including activities focused on youth and faith leaders.
- On 27 June, discussions between President Salva Kiir and former First Vice President Riek Machar in Khartoum culminated in agreement to a permanent ceasefire and the opening of humanitarian corridors, effective 30 June.
more
Expanding access to quality health services through task sharing
This report provides an overview of air pollution levels and associated health impacts in cities around the world. Since urban areas are often hotspots for poor air quality, city-level data can help to inform targeted efforts to curb urban air pollution and improve public health. This report draws o...n data from the Global Burden of Disease project and from peer-reviewed analyses led by Susan Anenberg of the George Washington University.
more
On 14 August 2024, the Director-General of the World Health Organization determined that the upsurge of mpox in a growing number of countries in Africa constitutes a new public health emergency of international concern (PHEIC) under the International Health Regulations (IHR) (2005)
This FY 2019 Malaria Operational Plan presents a detailed implementation plan for Burkina Faso, based on the strategies of PMI and the National Malaria Control Program (NMCP). It was developed in consultation with the NMCP and with the participation of national and international partners involved in... malaria prevention and control in the country. The activities that PMI is proposing to support fit in well with the national malaria control strategy and plan and build on investments made by PMI and other partners to improve and expand malaria-related services, including malaria grants from the Global Fund to Fight AIDS, Tuberculosis, and Malaria. This document briefly reviews the current status of malaria control policies and interventions in Burkina Faso, describes progress to date, identifies challenges and unmet needs to achieving the targets of the NMCP and PMI, and provides a description of activities that are planned with FY 2019 funding.
more
Downloaded from https://aidsinfo.nih.gov/guidelines on 10/19/2019
Developed by the HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV—A Working Group of the Office
of AIDS Research Advisory Council (OARAC)
DIAGNOSIS, MANAGEMENT OF UNCOMPLICATED AND SEVERE MALARIA
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
Clinical Guidelines. Diagnosis and Treatment Manual.